Vaxart Growth, Revenue, Number of Employees and Funding
Navigation
Overview
Estimated Revenue & Financials
- Vaxart's estimated revenue is currently $4.2M per year.
- Vaxart received $18.4M in venture funding in January 2015.
- Vaxart's estimated revenue per employee is $126030
- Vaxart's total funding is $58.6M.
Employee Data
- Vaxart has 33 Employees.
- Vaxart grew their employee count by -15% last year.
- Vaxart currently has 1 job openings.
Executive Contacts
| Name | Title |
|---|---|
| Sean Tucker | Founder/Chief Scientific Officer/Dir |
| John Harland | Vice President Financial Planning and Administration |
| Keith Gottlieb | Associate Director, Clinical Immunology |
| Patti Orozco Cronin | Sr. Director of Clinical Operations at Vaxart Inc. |
| Jaya Nair | Director Of Manufacturing Operations |
| David Ingamells | Vice President of Manufacturing |
| David Taylor | Chief Medical Officer |
| Eric Wenzel | Director, Clinical Development |
| Brant Biehn | Senior VP Commercial Operations |
| Uday Patel | Vice President Regulatory Affairs |
What Is Vaxart?
Vaxart is a clinical-stage company developing tablet vaccines based on its proprietary oral vaccine platform. The lead programs are prophylactic oral vaccines for seasonal influenza, RSV and norovirus, as well as a therapeutic vaccine for HPV types 16 and 18. Vaxart vaccines are convenient room temperature-stable tablets that are easy to administer, and that eliminate risk of needle-stick injury and medical waste associated with injectable vaccines. The company is listed on the NASDAQ exchange under ticker nymbol VXRT.
keywords:Biotechnology,Healthcare,Pharmaceuticals33
Number of Employees
$4.2M
Revenue (est)
1
Current Jobs
-15%
Employee Growth %
$58.6M
Total Funding
N/A
Valuation
N/A
Accelerator
B2B
Type
Similar Companies
| Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
| $6.2M | 43 | 10% | $53M | |
| $10.7M | 74 | 45% | ||
| $42M | 290 | 4% | ||
| $26.4M | 182 | 3% | ||
| $5.9M | 41 | 37% | ||
| $25.7M | 178 | 8% | ||
| $5.7M | 40 | 11% | $9M | |
| $4.2M | 33 | -15% | $58.6M | |
| $6M | 42 | 5% | ||
| $7.1M | 49 | -2% |
Vaxart News
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--. Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant ...
Stock analysts at Brookline Capital Management assumed coverage on shares of Vaxart (NASDAQ:VXRT) in a research note issued on ...
Vaxart (NASDAQ:VXRT) has been given a $2.00 target price by HC Wainwright in a research note issued on Wednesday, August 21st, ...
Vaxart Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2007-11-16 | $3.3M | A | Quantum Technology Partners, Life Science Angels | Article |
| 2010-03-05 | $12.5M | B | Care Capital of Princeton NJ | Article |
| 2013-08-07 | $20.0M | C | Article | |
| 2015-01-09 | $18.4M | Undisclosed | Care Capital | Article |
Vaxart Executive Hires
| Date | Name | Title | Reference |
|---|---|---|---|
| 2014-05-09 | John M. Harland | CFO | Article |
| 2016-02-10 | Samir Singh | SVP corporate development and strategy. | Article |
| 2018-04-20 | Brant Biehn | SVP Commercial Operations | Article |
| 2018-05-02 | David Taylor | Chief Medical Officer | Article |
Vaxart Acquisitions
| Date | Company Name | Amount | Notes | Reference |
|---|---|---|---|---|
| 2018-02-01 | Aviragen Therapeutics | Article | ||
| 2018-02-14 | Aviragen Therapeutics | Article |